Omentin-1 Level in Psoriatic Patients Treated With Narrowband Ultraviolet B Phototherapy Versus Acitretin

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05203354

Enrollment

Registered

2022-01-24

Start date

2018-09-01

Completion date

2021-08-15

Last updated

2022-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Brief summary

Studying the effects of Narrowband Ultraviolet B versus acitretin on psoriatic patients

Detailed description

Compare the effects of Narrowband Ultraviolet B versus acitretin on serum Omentin-1 level in psoriatic patients as case control study by dividing patients into 3 groups: group 1 include patients receive Narrowband Ultraviolet B, group II includes patients receive acitretin (0.5-1 mg/day) and control group. The duration of this study about 3 months after receving those interventions.

Interventions

RADIATIONNarrowband Ultraviolet B

patients will exposed to sessions of NB-UVB phototherapy twice weekly for 3 months

DRUGAcitretin

patients will received acitretin in dose 0.5-1 mg/kg daily for 3 months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients of both sexes with psoriasis vulgaris.

Exclusion criteria

* • Patients with history of malignancies, renal and liver diseases. * Patients received NB-UVB phototherapy in the last 6 months. * Patients treated with methotrexate or biologic agents and any systemic treatment of psoriasis.

Design outcomes

Primary

Measure	Time frame	Description
Decrease Omentin-1 serum level in both groups treated with NB-UVB and Acitretin	3 months	This outcome indicates potential role of Omentin-1 in psoriasis pathogenesis and its involvement in pathogenesis of obesity and related diseases as metabolic syndrome. So it will be concluded that high levels of this protein could be marker against obesity and related disorders including psoriasis. Omentin-1 can be valuable marker for psoriasis severity detected by its correlation with psoriasis area severity index (PASI) score and for evaluating the therapeutic outcomes

Secondary

Measure	Time frame	Description
Decrease PASI score in psoriatic patients	3 months	Decrease in PASI score in psoriatic patients after treatment with NB-UVB acitretin

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026